Answers are grounded in this paper and cite their sources.
Observational analysis found increased GLP-1 and chromogranin A in obesity, suggesting potential insufficient incretin action linked to type 2 diabetes.
Duodenal endocrine cells contribute to the incretin response, yet their changes in obesity and type 2 diabetes (T2D) remain controversial. We quantified expression of chromogranin A, glucagon-like peptide-1 (GLP-1), serotonin, and neuromedin U (NmU) in duodenal biopsies from 34 participants with obesity (19 with T2D, 15 without) and six healthy controls. Compared to controls, the patients with obesity showed significantly higher proportions of chromogranin A (p = 0.007), GLP-1 (p = 0.006), and serotonin (p = 0.013) expressing cells, irrespective of T2D status. GLP-1 expression correlated with HbA1C (r = 0.454, p = 0.005) and meal test glucose (r = 0.455, p = 0.0018) but not with insulin. Chromogranin A expression correlated with both GLP-1 (r = 0.486, p = 0.003) and serotonin (r = 0.475, p = 0.003), as well as BMI (r = 0.429, p = 0.007). NmU was detected in the lamina propria but did not differ among groups. For NmU, an association with insulin (incremental AUC, r = 0.363, p = 0.045) was observed. In conclusion, obesity was associated with hyperplasia of duodenal GLP-1, serotonin, and chromogranin A cells. The link between GLP-1 expression, HbA1C, and meal test glucose indicates that, despite increased numbers of GLP-1-producing cells, individuals with obesity may still experience insufficient incretin action. No evidence supported a role for NmU as a human decretin in these patients.
No takes yet. Share an insight, caveat, or question.
Bur et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: